Cite
Bi WL, Nayak L, Meredith DM, et al. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022;24(1):101-113doi: 10.1093/neuonc/noab118.
Bi, W. L., Nayak, L., Meredith, D. M., Driver, J., Du, Z., Hoffman, S., Li, Y., Lee, E. Q., Beroukhim, R., Rinne, M., McFaline-Figueroa, R., Chukwueke, U., McCluskey, C., Gaffey, S., Cherniack, A. D., Stefanik, J., Doherty, L., Taubert, C., Cifrino, M., LaFrankie, D., Graillon, T., Wen, P. Y., Ligon, K. L., Al-Mefty, O., Huang, R. Y., Muzikansky, A., Chiocca, E. A., Santagata, S., Dunn, I. F., & Reardon, D. A. (2022). Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro-oncology, 24(1), 101-113. https://doi.org/10.1093/neuonc/noab118
Bi, Wenya Linda, et al. "Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results." Neuro-oncology vol. 24,1 (2022): 101-113. doi: https://doi.org/10.1093/neuonc/noab118
Bi WL, Nayak L, Meredith DM, Driver J, Du Z, Hoffman S, Li Y, Lee EQ, Beroukhim R, Rinne M, McFaline-Figueroa R, Chukwueke U, McCluskey C, Gaffey S, Cherniack AD, Stefanik J, Doherty L, Taubert C, Cifrino M, LaFrankie D, Graillon T, Wen PY, Ligon KL, Al-Mefty O, Huang RY, Muzikansky A, Chiocca EA, Santagata S, Dunn IF, Reardon DA. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 Jan 05;24(1):101-113. doi: 10.1093/neuonc/noab118. PMID: 34015129.
Copy
Download .nbib